# ATG Versus Basiliximab in Kidney Transplant Displaying Low Immunological Risk But High Susceptibility to DGF

> **NCT02056938** · PHASE4 · TERMINATED · sponsor: **Nantes University Hospital** · enrollment: 19 (actual)

## Conditions studied

- Kidney Transplantation

## Interventions

- **DRUG:** Anti-Thymocyte Globulins treatment
- **DRUG:** Basiliximab treatment

## Key facts

- **NCT ID:** NCT02056938
- **Lead sponsor:** Nantes University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-06
- **Primary completion:** 2017-02
- **Final completion:** 2017-02
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** recruitment issues
- **Last updated:** 2017-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02056938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02056938, "ATG Versus Basiliximab in Kidney Transplant Displaying Low Immunological Risk But High Susceptibility to DGF". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02056938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*